ISEE
Closed
Iveric Bio Inc
39.95
+0.15 (+0.38%)
Last Update: 11 Jul 2023 16:30:00
Yesterday: 39.8
Day's Range: 39.95 - 39.95
Send
sign up or login to leave a comment!
When Written:
26.49
IVERIC bio Inc. is a biopharmaceutical company that is focused on the discovery and development of innovative therapies for the treatment of ophthalmic diseases. The company's pipeline includes drugs for the treatment of age-related macular degeneration, diabetic macular edema, and other retinal diseases.
The company was founded in 2017 as a spin-off from Ophthotech Corporation, and is headquartered in New York City. IVERIC bio's lead drug candidate is Zimura, a complement C5 inhibitor that is being developed for the treatment of geographic atrophy, a leading cause of blindness in the elderly.
In addition to Zimura, IVERIC bio is also developing a gene therapy for the treatment of Best disease, an inherited retinal disease that causes progressive vision loss. The company's gene therapy platform is based on adeno-associated virus (AAV) vectors, which are designed to deliver therapeutic genes to the retina.
Overall, IVERIC bio is focused on developing innovative therapies that can improve the lives of patients with ophthalmic diseases, and is committed to advancing the field of ophthalmology through cutting-edge research and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company was founded in 2017 as a spin-off from Ophthotech Corporation, and is headquartered in New York City. IVERIC bio's lead drug candidate is Zimura, a complement C5 inhibitor that is being developed for the treatment of geographic atrophy, a leading cause of blindness in the elderly.
In addition to Zimura, IVERIC bio is also developing a gene therapy for the treatment of Best disease, an inherited retinal disease that causes progressive vision loss. The company's gene therapy platform is based on adeno-associated virus (AAV) vectors, which are designed to deliver therapeutic genes to the retina.
Overall, IVERIC bio is focused on developing innovative therapies that can improve the lives of patients with ophthalmic diseases, and is committed to advancing the field of ophthalmology through cutting-edge research and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








